Regeneron Pharmaceuticals Inc Quick Ratio (REGN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Regeneron Pharmaceuticals Inc   (NASDAQ: REGN)

Regeneron Pharmaceuticals Inc 's Quick Ratio

REGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regeneron Pharmaceuticals Inc 's Cash & cash equivalent grew by 16.34 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Regeneron Pharmaceuticals Inc 's Quick Ratio to 1.5, Quick Ratio remained below Regeneron Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 319 other companies have achieved higher Quick Ratio than Regeneron Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1318, from total ranking in the second quarter 2026 at 1606.

Explain Quick Ratio?
How much Cash & cash equivalents REGN´s has?
What are REGN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

REGN Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 59.87 % 73.64 % 27.29 % 15.04 % 27.88 %
Y / Y Cash & cash equivalent Change 10.16 % 7.03 % 4.84 % -4.52 % -13.81 %
Quick Ratio MRQ 1.5 1.45 2.33 2.26 2.18
REGN's Total Ranking # 1318 # 1606 # 1513 # 1475 # 1334
Seq. Current Liabilities Change 12.14 % 47.42 % -1.67 % -1.65 % 21.8 %
Seq. Cash & cash equivalent Change 16.34 % -8.67 % 1.73 % 1.91 % 13.04 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 320
Healthcare Sector # 566
Overall Market # 1649


Quick Ratio Statistics
High Average Low
4.49 2.12 0.76
(Dec 31 2010)   (Dec 31 2016)




Financial Statements
Regeneron Pharmaceuticals Inc 's Current Liabilities $ 6,202 Millions Visit REGN's Balance sheet
Regeneron Pharmaceuticals Inc 's Cash & cash equivalent $ 9,301 Millions Visit REGN's Balance sheet
Source of REGN's Sales Visit REGN's Sales by Geography


Cumulative Regeneron Pharmaceuticals Inc 's Quick Ratio

REGN's Quick Ratio for the trailling 12 Months

REGN Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 44.8 % 36 % 19.73 % 12.08 % 11.21 %
Y / Y Cash & cash equivalent TTM Growth 4.15 % -2.4 % -10 % -16.02 % -18.78 %
Quick Ratio TTM 1.8 1.99 2.27 2.38 2.5
Total Ranking TTM # 1788 # 1965 # 1512 # 1529 # 1553
Seq. Current Liabilities TTM Growth 13.68 % 16.03 % 5.82 % 3.74 % 6.77 %
Seq. Cash & cash equivalent TTM Growth 2.54 % 1.58 % 1.23 % -1.22 % -3.91 %

Quick ratio ranking by company, industry and sector >> Back to REGN Financial Strength Comparisons >> Go to Compare REGN Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $6,202.10 millions, cumulative Quick Ratio decreased to 1.8 above the REGN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Regeneron Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4029.

Explain Quick Ratio?
How much Cash & cash equivalents REGN´s has?
What are REGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 439
Healthcare Sector # 902
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
2.32 0.98 0.57
(Mar 31 2012)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Revelation Biosciences Inc   3.92 $ 9.122  Millions$ 2.328  Millions
Lyell Immunopharma Inc   3.83 $ 177.106  Millions$ 46.271  Millions
Rapport Therapeutics Inc   3.68 $ 74.754  Millions$ 20.302  Millions
Seaport Therapeutics Inc   3.60 $ 61.552  Millions$ 17.106  Millions
Cytokinetics Incorporated  3.20 $ 1,130.021  Millions$ 353.419  Millions
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions
Ptc Therapeutics inc   2.74 $ 2,127.918  Millions$ 776.076  Millions
Beone Medicines Ltd   2.67 $ 5,955.905  Millions$ 2,233.923  Millions
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Ironwood Pharmaceuticals inc   2.49 $ 86.376  Millions$ 34.733  Millions
Opko Health Inc   2.37 $ 384.036  Millions$ 162.356  Millions
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions
Dogwood Therapeutics inc   2.28 $ 4.948  Millions$ 2.174  Millions
Ardelyx inc   2.23 $ 285.338  Millions$ 127.805  Millions
Schrodinger Inc   2.20 $ 366.358  Millions$ 166.292  Millions
Stoke Therapeutics Inc   2.19 $ 107.271  Millions$ 48.977  Millions
Maravai Lifesciences Holdings Inc   2.14 $ 73.023  Millions$ 34.160  Millions
Ernexa Therapeutics Inc   2.13 $ 5.575  Millions$ 2.614  Millions
Madrigal Pharmaceuticals Inc   2.12 $ 962.387  Millions$ 454.244  Millions
Corcept Therapeutics Inc  2.09 $ 370.703  Millions$ 177.675  Millions
Dianthus Therapeutics Inc   1.95 $ 55.686  Millions$ 28.515  Millions
Xeris Biopharma Holdings Inc   1.95 $ 262.164  Millions$ 134.479  Millions
Ars Pharmaceuticals Inc   1.95 $ 138.354  Millions$ 70.995  Millions
Lite Strategy Inc   1.92 $ 4.281  Millions$ 2.234  Millions
Mineralys Therapeutics Inc   1.91 $ 101.273  Millions$ 53.075  Millions

Date modified: 2026-10-31T17:28:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.